Identify the material
The exact extract, composition and delivery format matter.
RESEARCH CONTEXT
Ingredient research, with its limits made clear.
The sources below inform our development questions. They are not clinical studies of ELX-13 and do not establish benefits for the finished drink.
ELX-13 has not established finished-product effects on lifespan, biological ageing, cell regeneration, mood or digestive conditions.
Olive-leaf extract research
A 2013 crossover study in 46 overweight middle-aged men tested a specific olive-leaf extract for 12 weeks. The daily intervention supplied 51.1 mg oleuropein and 9.7 mg hydroxytyrosol.
This was a particular extract used in a particular study population. It was not ELX-13, and its composition is not a final ELX-13 specification.
Saffron-extract research
A 2026 placebo-controlled trial studied 28 mg daily of the named affron saffron extract for 12 weeks in 86 women aged 50–70 with low mood and poor sleep. It reported improvement in the primary depression-score outcome, but no significant difference in estimated facial skin age.
The extract manufacturer funded the study. The trial does not establish age reversal or a benefit for ELX-13. Results for a specified extract and study population cannot automatically be transferred to a different saffron material or beverage.
Mastic-resin research
A 2010 study in 148 people with functional dyspepsia examined 350 mg of Chios mastic gum three times a day for three weeks.
This was a patient study using a divided daily dose. It does not establish a digestive-treatment claim or a serving instruction for ELX-13.
Understanding vitamin B3
Nicotinamide is a form of vitamin B3. It is distinct from nicotinic acid, nicotinamide riboside, NMN and NAD+.
A nutrient reference or a competitor’s ingredient amount does not establish the final ELX-13 dose or a longevity effect.
How we read the research
Check the study context
Dose, duration and the people studied affect what a result can tell us.
Separate ingredient and product evidence
An ingredient study cannot be presented as an ELX-13 product result.
Current development record
The website follows the final ELX-13 investor package dated 23 September 2026. Final formula, sourcing, packaging, shelf life and label review remain open. The proposed recipes are development briefs, not finished products.
Current product and research record
The confirmed brief is three still 355 ml botanical drinks. Nutrient amounts remain subject to formulation and review. The research record includes the 2026 saffron trial and its limits; no ingredient study is presented as an ELX-13 result.
Research record updated 23 September 2026.